twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2024
vol. 126
 
Share:
Share:
abstract:
Review paper

Uveitis associated with elevation of intraocular pressure – what is the optimal therapy?

Agnieszka Kubicka-Trząska
1, 2

  1. Department of Ophthalmology, Jagiellonian University Medical College, Krakow, Poland
  2. Department of Ophthalmology and Ocular Oncology, University Hospital in Krakow, Poland
KLINIKA OCZNA 2024, 126, 1: 1-7
Online publish date: 2023/12/09
View full text Get citation
 
PlumX metrics:
Uveitis is the fifth leading cause of blindness in developed countries. The ocular complications of uveitis are not only related to the inflammation itself but also result from glucocorticosteroid therapy, which is the mainstay of treatment. Glucocorticosteroids may be used as eye drops; periocular, intravitreal, suprachoroidal injections; or systemically. One of the most serious side effect of glucocorticosteroid therapy is glucocorticosteroid-induced ocular hypertension (SIOH), which can lead to the glucocorticosteroid-induced secondary glaucoma (SIG). If untreated, SIG may cause irreversible blindness. Therefore, it is important to monitor intraocular pressure (IOP) in the course of glucocorticosteroid therapy. One of the risk factors for SIG is the use of glucocorticosteroids with high anti-inflammatory potency, such as prednisolone or dexamethasone. On the other hand, glucocorticosteroids with lower potency, such as loteprednol or fluorometholone, show a low risk of SIOH. Such response to glucocorticosteroids occurs in approximately 35% of the population; these individuals are referred as “steroid-responders”. If SIG is diagnosed, it is necessary to modify the glucocorticosteroid treatment to maintain a balance between controlling inflammation and normalizing the IOP. β-blockers and carbonic anhydrase inhibitors are the first-line anti-glaucoma drugs in the treatment of SIG in patients with uveitis. α-2 agonists are classified as second-line drugs. Prostaglandins and hyperosmotic agents are of limited use, and miotics are contraindicated in uveitic patients.

The aim of the article is to present the classification and contemporary knowledge about the pathophysiology and pharmacological management of uveitis associated with increased IOP.
keywords:

uveitis, glucocorticosteroids, uveitic glaucoma, glucocorticosteroid-induced ocular hypertension, steroid-induced glaucoma

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.